- Conditions
- Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
- Interventions
- Eplontersen, Placebo
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 39 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 105
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Transthyretin Amyloid Cardiomyopathy (ATTR CM)
- Interventions
- NNC6019-0001
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Los Angeles, California • Stanford, California + 5 more
- Conditions
- Hereditary Transthyretin Amyloidosis With Polyneuropthy
- Interventions
- TEGSEDI
- Drug
- Lead sponsor
- Akcea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Rosedale, New York
- Conditions
- Hereditary Amyloidosis, Transthyretin-Related
- Interventions
- neurofilament light chain, In-vivo Meissner Corpuscle imaging, Nerve conduction study
- Diagnostic Test
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 30 Years to 90 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Transthyretin Amyloidosis
- Interventions
- I 124-Evuzamitide
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 50 Years to 105 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Amyloid Cardiomyopathy, Transthyretin-Related
- Interventions
- AG10 oral tablet, Placebo Oral Tablet
- Drug
- Lead sponsor
- Eidos Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Transthyretin Amyloidosis
- Interventions
- Cardiac MRI
- Diagnostic Test
- Lead sponsor
- The Christ Hospital
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Interventions
- Vutrisiran
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 19 more
- Conditions
- Amyloid Cardiomyopathy, Transthyretin-Related
- Interventions
- Acoramidis (AG10)
- Drug
- Lead sponsor
- Eidos Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 21 more
- Conditions
- Transthyretin Amyloidosis, Transthyretin Amyloidosis With Cardiomyopathy, Transthyretin Amyloidosis With Polyneuropathy
- Interventions
- None ( observational study )
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Transthyretin Gene Mutations, Transthyretin Amyloidosis
- Interventions
- None. Observational Study.
- Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,718 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2023
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more
- Conditions
- Transthyretin (TTR) Amyloid Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Amyloid, Amyloidosis, Spinal Stenosis, Transthyretin Amyloidosis, Primary Amyloidosis of Light Chain Type
- Interventions
- Biopsy
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 200 participants
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
- Interventions
- AG10, Placebo
- Drug
- Lead sponsor
- Eidos Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Amyloidogenic Transthyretin (ATTR) Amyloidosis
- Interventions
- PRX004
- Drug
- Lead sponsor
- Prothena Biosciences Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • Portland, Oregon + 1 more
- Conditions
- Transthyretin Amyloid Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Jacksonville, Florida • Chicago, Illinois + 3 more
- Conditions
- Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis
- Interventions
- Not listed
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2033
- U.S. locations
- 13
- States / cities
- La Jolla, California • Los Angeles, California • Jacksonville, Florida + 10 more
- Conditions
- Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
- Interventions
- Cardiac MRI
- Diagnostic Test
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Portland, Oregon
- Conditions
- Cardiac Amyloidosis, Heart Diseases, TTR Cardiac Amyloidosis
- Interventions
- Beta blocker
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Amyloidosis, Amyloid, Amyloid Neuropathies, Familial, Amyloid Cardiomyopathy, Amyloid - Primary, Transthyretin Amyloidosis, AL Amyloidosis
- Interventions
- Not listed
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
- Interventions
- Scintigraphy scan
- Diagnostic Test
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- New York, New York • Durham, North Carolina • Cleveland, Ohio + 1 more
- Conditions
- Amyloidosis; Systemic
- Interventions
- 124I-AT03
- Drug
- Lead sponsor
- Attralus, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Transthyretin Amyloidosis With Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Beverly Hills, California • Naples, Florida + 8 more
- Conditions
- Amyloidosis, Transthyretin Amyloidosis
- Interventions
- 124I-Evuzamitide
- Diagnostic Test
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Portland, Oregon